Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Saved in:

書目詳細資料
Main Authors:	Sai‐Hong Ignatius Ou, Ramaswamy Govindan, Keith D. Eaton, Gregory A. Otterson, Martin Gutierrez, Alain C. Mita, Athanassios Argiris, Nicoletta Brega, Tiziana Usari, Weiwei Tan, Steffan N. Ho, Francisco Robert
格式:	Artigo
語言:	英语
出版:	2016
在線閱讀:	https://doi.org/10.1016/j.jtho.2016.09.131 http://www.jto.org/article/S1556086416311194/pdf
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
由: Ou, Sai-Hong Ignatius, et al.
出版: (2016)

Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment
由: Klempner, Samuel J., et al.
出版: (2014)

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
由: Alexander Drilon, et al.
出版: (2020)

Crizotinib in Patients With MET-Amplified NSCLC
由: D. Ross Camidge, et al.
出版: (2021)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
由: Drilon, Alexander, et al.
出版: (2020)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
由: Xu, Huiping, et al.
出版: (2021)

Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
由: O’Mahar, Shannon E., et al.
出版: (2011)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
由: Sai‐Hong Ignatius Ou
出版: (2011)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
由: Ou, Sai-Hong Ignatius
出版: (2011)

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
由: El‑Khoueiry, Anthony B., et al.
出版: (2018)

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)
由: Ou, Sai‐Hong Ignatius, et al.
出版: (2016)

Heart rate decrease during crizotinib treatment and potential correlation to clinical response
由: Sai‐Hong Ignatius Ou, et al.
出版: (2013)

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007)
由: Sai‐Hong Ignatius Ou, et al.
出版: (2016)

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
由: Sai‐Hong Ignatius Ou, et al.
出版: (2011)

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
由: Benjamin Solomon, et al.
出版: (2014)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
由: Makoto Nishio, et al.
出版: (2017)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
由: Nishio, Makoto, et al.
出版: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
由: Yoshimura, Katsuhiro, et al.
出版: (2017)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
由: Van Der Steen, Nele, et al.
出版: (2020)

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
由: Maria Carmela Piccirillo, et al.
出版: (2022)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
由: Zhu, Viola W, et al.
出版: (2019)

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
由: Li, Tianhong, et al.
出版: (2016)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
由: A. Shaw, et al.
出版: (2019)

Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
由: Ou, Sai-Hong Ignatius, et al.
出版: (2012)

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
由: Ou, Sai-Hong Ignatius, et al.
出版: (2015)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
由: Honeywell, Richard J., et al.
出版: (2020)

Crizotinib for the Treatment of <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
由: Sai‐Hong Ignatius Ou, et al.
出版: (2012)

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
由: Alice T. Shaw, et al.
出版: (2014)

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
由: Giorgio V. Scagliotti, et al.
出版: (2015)

Alectinib Induces a Durable (&gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
由: Sai‐Hong Ignatius Ou, et al.
出版: (2015)

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
由: Yi‐Long Wu, et al.
出版: (2018)

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
由: Daniel B. Costa, et al.
出版: (2011)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
由: Zhang, Yongchang, et al.
出版: (2022)

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
由: Weickhardt, Andrew J., et al.
出版: (2013)

Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations
由: Rafael Caparica, et al.
出版: (2016)

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
由: Andrew Weickhardt, et al.
出版: (2013)

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification
由: Justin F. Gainor, et al.
出版: (2016)

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
由: Mark A. Socinski, et al.
出版: (2018)

Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer
由: Gross, Neil D., et al.
出版: (2014)

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
由: Neil D. Gross, et al.
出版: (2014)